Robbins LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action
Robbins LLP announces that a class action complaint was filed against Alexion Pharmaceuticals, Inc. (NASDAQGS: ALXN) in the U.S. District Court for the Southern District of New York. The complaint is brought on behalf of all purchasers of Alexion securities between February 10, 2014 and November 9, 2016, for alleged violations of the Securities Exchange Act of 1934 by Alexion’s officers and directors. Alexion, a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. If you suffered a loss in Alexion and wish to serve as lead plaintiff in this class action, you must petition the Court by January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Alexion Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.